CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced
The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches
New modality drugs, or advanced oligonucleotide therapeutics, refer to innovative approaches that go beyond traditional small molecule approaches to
How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
Imagine a world where developing new medicines is faster, cheaper, and less reliant on the use of animals for testing. Novel multi-organ in vitro